IP Library Granted Patent US 10,463,062
Granted Patent B2
US 10,463,062 · App. 15/524,015 · Granted Nov 5, 2019

Microbial production of steviol glycosides

Inventors: Ryan Philippe (Cambridge, MA); Ajikumar Parayil Kumaran (Cambridge, MA); Jason Donald (Cambridge, MA); Krishna Patel (Cambridge, MA); Swati Gupta (Cambridge, MA); Ryan Lim (Cambridge, MA); Liwei Li (Cambridge, MA)
Assignee: MANUS BIO INC.
A23L2/60A23L27/36C12N9/0073C12N9/1048C12N9/1051C12P19/56C12Y114/13079C12Y204/01017A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,463,062
App. No.
15/524,015
Granted
Nov 5, 2019
Kind
B2
Abstract

The invention provides methods for making steviol glycosides, including RebM and glycosylation products that are minor products in stevia leaves, and provides enzymes, encoding polynucleotides, and host cells for use in these methods. The invention provides engineered enzymes and engineered host cells for producing steviol glycosylation products, such as RebM, at high purity and/or yield. The invention further provides methods of making products containing steviol glycosides, such as RebM, including food products, beverages, oral care products, sweeteners, and flavoring products.

Claims (49)

1. A method for making Rebaudioside M (RebM) or Rebaudioside D (RebD), comprising: providing a host cell producing RebM or RebD from steviol through a plurality of uridine diphosphate dependent glycosyltransferase enzymes (UGT), the UGT enzymes comprising one or more of:

(a) a modified UGT enzyme having an increase in 1-2′ glycosylating activity at C19 of Rebaudioside A (RebA) as compared to its parent UGT enzyme, without substantial loss of 1-2′ glycosylating activity at C13 of steviolmonoside as compared to its parent UGT enzyme, and

(b) a modified UGT enzyme having an increase in 1-3′ glycosylating activity at C19 of Rebaudioside D (RebD) as compared to its parent UGT enzyme, without substantial loss of 1-3′ glycosylating activity at C13 of stevioside as compared to its parent UGT enzyme;

and culturing the host cell under conditions for producing the RebM or RebD;

wherein the UGT enzyme having an increase in 1-2′ glycosylating activity at C19 of RebA is a circular permutant of its parent UGT enzyme and the UGT enzyme having an increase in 1-3′ glycosylating activity at C19 of RebD is a circular permutant of its parent UGT enzyme.

2. The method of claim 1 , wherein:

(a) the 1-2′ glycosylating activity at C19 of Rebaudioside A (RebA) is equal to or better than the 1-2′ glycosylating activity at C13 of steviolmonoside: and/or

(b) the 1-3′ glycosylating activity at C19 of Rebaudioside D (RebD) is equal to or better than the 1-3′ glycosylating activity at C13 of stevioside.

3. The method of claim 1 , wherein the cell expresses only one UGT enzyme having 1-2′ glycosylating activity at C13 of steviolmonoside, and/or expresses only one UGT enzyme having 1-3′ glycosylating activity at C13 of stevioside.

4. The method of claim 1 , wherein the cell expresses both the UGT enzyme having an increase in 1-2′ glycosylating activity at C19 of RebA that is a circular permutant of its parent UGT enzyme and the UGT enzyme having an increase in 1-3′ glycosylating activity at C19 of RebD that is a circular permutant of its parent UGT enzyme.

5. The method of claim 1 , wherein the UGT enzyme having 1-2′ glycosylating activity is OsUGT1-2 or SrUGT91D2, or SrUGT91D1, or derivative thereof having increased glycosylating activity at C19 of RebA as compared to its parent UGT enzyme.

6. The method of claim 5 , wherein the UGT enzyme having 1-2′ glycosylating activity is a circular permutant of OsUGT1-2 comprising one or more amino acid substitutions, deletions, and/or insertions that increase 1-2′ glycosylating activity at C19 of RebA as compared to its parent UGT enzyme.

7. The method of claim 6 , wherein the UGT enzyme having 1-2′ glycosylating activity is a circular permutant of OsUGT1-2 having a cut site corresponding to a position within 190 to 210 of SEQ ID NO: 7, and having a linker sequence between the amino acids that correspond to the N-terminal and C-terminal residues of SEQ ID NO: 7, and wherein the linker optionally has a length of from 2 to 25 amino acids.

8. The method of claim 5 , wherein the UGT enzyme having 1-2′ glycosylating activity is SrUGT91D2, and which is a circular permutant comprising one or more amino acid substitutions, insertions, and/or deletions that increase glycosylating activity of C19 of RebA as compared to its parent UGT enzyme.

9. The method of claim 1 , wherein the UGT enzyme having 1-2′ glycosylating activity is MbUGT1,2-2 (SEQ ID NO: 45) or derivative thereof.

10. The method of claim 1 , wherein the UGT enzyme having 1-3′ glycosylating activity is a derivative of SrUGT76G1, which is a circular permutant comprising one or more amino acid substitutions, insertions, and/or deletions increasing glycosylation activity of C19 of RebD as compared to its parent UGT enzyme.

11. The method of claim 1 , wherein the UGT enzyme having 1-3′ glycosylating activity is a derivative of SrUGT76G1 that includes an amino acid substitution at one or more of positions 200, 284, and/or 379, wherein amino acid positions are numbered according to SEQ ID NO:3.

12. The method of claim 1 , wherein the host cell further comprises a UGT enzyme that converts steviol to steviolmonoside.

13. The method of claim 12 , wherein the UGT enzyme that converts steviol to steviolmonoside is SrUGT85C2, or derivative thereof.

14. The method of claim 1 , wherein the host cell further comprises a UGT enzyme that converts steviolbioside to stevioside.

15. The method of claim 14 , wherein the UGT enzyme that converts steviolbioside to stevioside is SrUGT74G1, or derivative thereof.

16. The method of claim 1 , wherein the host cell produces steviol substrate through an enzymatic pathway comprising a kaurene synthase (KS), kaurene oxidase (KO), and a kaurenoic acid hydroxylase (KAH), the host cell further comprising a cytochrome P450 reductase (CPR) for regenerating one or more of the KO and KAH enzymes.

17. The method of claim 1 , wherein the host cell expresses a geranylgeranyl pyrophosphate synthase (GGPPS), which is optionally of Taxus canadensis, Abies grandis, Aspergillus nidulans, Stevia rebaudiana, Gibberella fujikuroi , Marine bacterium 443, Paracoccus haeundaensis, Chlorobium tepidum, Mus musculus, Thalassiosira pseudonana, Streptomyces melanosporofaciens, Streptomyces clavuligerus, Sulfulubus acidocaldarius, Synechococcus sp., Synechocystis sp., Arabidopsis thaliana, Thermotogo maritime, Corynebacterium glutamicum, Therms thermophillus, Pyrobaculum calidifontis , or derivatives thereof.

18. The method of claim 1 , wherein the host cell expresses a pathway producing iso-pentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP).

19. The method of claim 18 , wherein the host cell is prokaryotic or eukaryotic.

20. The method of claim 19 , wherein the host cell is E. coli, Bacillus subtillus , or Pseudomonas putida.

21. The method of claim 19 , wherein the host cell is a species of Saccharomyces, Pichia , or Yarrowia , including Saccharomyces cerevisiae, Pichia pastoris , and Yarrowia lipolytica.

22. The method of claim 1 , wherein the host cell comprises the following heterologously expressed genes:

Taxus canadensis GGPPS or derivative thereof,

Phaeosphaeria sp. PsCK (a copalyl diphosphate-kaurene synthase) or derivative thereof,

Stevia rebaudiana KO or derivative thereof,

Arabidopsis thaliana KAH or derivative thereof,

Stevia rebaudiana CPR or derivative thereof,

Stevia rebaudiana UGT85C2 or derivative thereof,

Stevia rebaudiana UGT74G I or derivative thereof or MbUGTC 19 or derivative thereof,

Stevia rebaudiana UGT76G I or derivative thereof or MbUGT1-3 or derivative thereof, and

Stevia rebaudiana UGT91 D2 or OsUGT1-2 or MbUGT1-2 or derivative thereof.

23. The method of claim 1 , wherein the host cell comprises the following heterologously expressed genes:

Corynebacterium glutmnncun GGPS or derivative thereof,

Erwina tracheiphila copalyl diphosphate synthase (CPPS) or derivative thereof,

Erwina tracheiphila KS or derivative thereof,

Stevia rebaudiana KO or derivative thereof,

Arabidopsis thaliana KAH or derivative thereof,

Stevia rebaudiana CPR or derivative thereof,

Stevia rebaudiana UGT85C2 or derivative thereof,

Stevia rebaudiana UGT74G1 or derivative thereof or MbUGTC19 or derivative thereof or MbUGTC19-2 or derivative thereof,

Stevia rebaudiana UGT76G1 or derivative thereof or MbUGT1-3 or derivative thereof, and

Stevia rebaudiana UGT91 D2 or OsUGT1-2 or MbUGT1,2-2 or derivative thereof.

24. The method of claim 1 , further comprising recovering the RebM or RebD from culture media.

Assignments (7)
SECURITY INTEREST Recorded Sep 8, 2025
From: MANUS BIO INC.; STO.PERU I LLC; STO.PERU II LLC; MANUS INTERMEDIATE INC.; MANUS INSCRIPTA, INC.
To: SYMBIOTIC CAPITAL AGENCY LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT
Reel/Frame 072836/0255 →
RELEASE OF SECURITY INTEREST Recorded May 9, 2025
From: EICF AGENT LLC
To: MANUS BIO INC.
Reel/Frame 071247/0658 →
SECURITY AGREEMENT Recorded Aug 23, 2021
From: MANUS BIO INC
To: EICF AGENT LLC
Reel/Frame 057255/0345 →
RELEASE OF SECURITY INTEREST Recorded Aug 23, 2021
From: ARBORETUM INVESTMENT ADVISORS, LLC, (F/K/A SQN INVESTMENT ADVISORS, LLC)
To: MANUS BIO INC
Reel/Frame 057262/0915 →
CHANGE OF NAME Recorded Jul 2, 2019
From: MANUS BIOSYNTHESIS, INC.
To: MANUS BIO INC.
Reel/Frame 049670/0662 →
SECURITY INTEREST Recorded Jun 29, 2018
From: MANUS BIO INC.
To: SQN INVESTMENT ADVISORS, LLC, AS AGENT
Reel/Frame 046245/0272 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 7, 2018
From: KUMARAN, AJIKUMAR PARAYIL; PHILIPPE, RYAN; DONALD, JASON; PATEL, KRISHNA; GUPTA, SWATI; LIM, RYAN; LI, LIWEI
To: MANUS BIOSYNTHESIS INC.
Reel/Frame 045133/0487 →
Continuity (2)
Provisional Application 62075644 · Nov 5, 2014
Related Publication 20170332673A1 · Nov 23, 2017
Cited By (2)
US 12,209,267 US 12,478,082